The Beijing Intellectual Property Court has recently accepted a utility model patent infringement case filed by Suzhou Jiashu Biology against Shanghai Yinno Medicine and Beijing JD Pharmacy. While JD Pharmacy is listed as a defendant, a common tactic to establish jurisdiction, the core dispute lies between Jiashu Biology and INNOGEN-B (02591).
Based on the companies' business profiles and public information, the lawsuit appears to target the pre-filled auto-injector pen used with Yinno's product, Yinuo Qing (Esupaglutide α injection). For INNOGEN-B, which has commercialized only this single product, the potential legal, operational, and financial impacts of this litigation warrant close attention.
Clear Accountability Under the MAH System Links Legal Strategy to Product Distribution
As the Marketing Authorization Holder (MAH) for Yinuo Qing, INNOGEN-B holds the drug registration certificate and is responsible for centralized procurement bidding and national channel management. By suing the MAH directly instead of the injector manufacturer, Jiashu Biology ensures that a successful infringement ruling would mandate a halt to sales of all products nationwide, including finished goods already in hospitals and retail pharmacies.
The MAH's absolute control over product distribution makes it directly liable for enforcement and makes a product stop-sale and recall operationally feasible. In contrast, suing only the upstream contract manufacturer would not effectively prevent INNOGEN-B from using existing inventory of pens for final filling and market release. This legal strategy directly ties legal accountability to product supply, posing a more immediate threat to a company reliant on a single product.
Transparent Basis for Damage Calculations Enables Quantifiable Financial Impact
INNOGEN-B is listed on the Hong Kong Stock Exchange, and Yinuo Qing is currently its only commercially available product, which is also included in the National Reimbursement Drug List. These factors create high transparency regarding the sales volume, pricing, and profitability of the allegedly infringing product.
As a listed company, INNOGEN-B must disclose revenue contribution and shipment volumes of its core product in annual reports. Sales volumes and prices through the centralized procurement channel can also be cross-verified with public procurement data. In patent infringement cases, plaintiffs can use this publicly available information to calculate damages with relative precision. This data accessibility lowers the plaintiff's burden of proof and provides INNOGEN-B with a clearer expectation of potential financial claims.
Supply Chain Adjustments Could Trigger Post-Marketing Change Management Procedures
The pre-filled auto-injector pen for Yinuo Qing is a procured component. If the court ultimately rules to stop the infringement, INNOGEN-B would need to switch injector suppliers or modify the product design. This change would trigger post-marketing change management regulations, requiring the company to submit a supplemental application to the National Medical Products Administration, file a record with provincial authorities, or include it in an annual report, depending on the significance of the change.
Major changes, in particular, would require a full set of supporting data, including verification of dose uniformity for the drug delivery system, packaging material compatibility studies, and long-term stability testing, with a review cycle typically measured in years. Even moderate changes require several months to complete filing and submission of research data. Supply interruptions would be difficult to avoid during this process. Given that the GLP-1 market where Yinuo Qing competes already has multiple reimbursed products targeting the same pathway, ample alternatives exist. A supply gap could lead to prescription switching and patient loss, impacting market share.
Single-Product Structure Amplifies Supply Chain Compliance Risks
INNOGEN-B currently has only Yinuo Qing on the market, with other pipeline assets still in the pre-clinical stage, making it a typical single-product-dependent company. This patent lawsuit highlights the ultimate responsibility that the MAH bears for intellectual property risks in the upstream supply chain under the MAH system.
While current regulations primarily focus on the MAH's lifecycle responsibility for drug quality, in judicial practice, the MAH, as the core entity for product registration and distribution, can be held accountable for patent compliance issues arising from any link in its supply chain, with consequences ultimately reaching the end market. This risk transmission mechanism implies that pharmaceutical companies must incorporate IP due diligence into their supplier onboarding and management processes and establish contingency plans. For companies with a single-product structure, the patent compliance capability of their supply chain is not just a legal issue but is directly linked to the commercial stability of their core product.
In summary, the potential impact of this lawsuit on INNOGEN-B extends beyond a single legal dispute, touching on drug supply stability, financial compensation expectations, and market access order. The case is still in its early stages, and the final outcome awaits a judicial ruling. However, the supply chain intellectual property compliance management issues it exposes are instructive for innovative drug companies operating under the MAH model. Against the backdrop of increasing homogeneity in the innovative drug competitive landscape, patent strategy and compliance control around supporting elements like drug delivery devices are becoming key variables affecting the sustainability of a product's commercialization.
Comments